Status:
TERMINATED
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
The Vaccine Company
Conditions:
Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Primary aim: 1. To determine the immunologic response, using a PR1-HLA-A2 tetramer assay, to 4 subcutaneous (SQ) injections of TVC-PR1 vaccine formulated in Montanide ISA 51 VG followed by granulocyt...
Detailed Description
MDS cells over-produce proteins found in normal bone marrow cells. These proteins can be used to stimulate the body's immune system to kill the MDS cells. PR-1 is a peptide derived from a protein, and...
Eligibility Criteria
Inclusion
- Must understand and voluntarily sign an informed consent form
- Age \>/= 18 years at the time of signing the informed consent form
- Must be able to adhere to the study visit schedule and other protocol requirements
- HLA-A2 positive at one allele
- Diagnosis of myelodysplastic syndrome (MDS) and must meet all the following criteria
- French-American-British (FAB) Class Refractory anemia (RA), Refractory Anemia with Excess Blasts (RAEB), refractory anemia with ringed sideroblasts (RARS)
- World Health Organization(WHO) Classification refractory anemia (RA), refractory anemia with ringed sideroblasts(RARS), refractory cytopenia with multilineage dysplasia (RCMD), refractory cytopenia with ringed sideroblasts (RCMD-RS) , refractory anemia with excess blasts type 1 (RAEB-1)
- Less than 20% blasts on marrow aspirate
- International Prognostic Scoring System (IPSS) risk groups Intermediate 1 or transfusion dependent low risk.
- Both de novo and therapy related MDS are eligible
- Eastern Cooperative Oncology Group (ECOG) performance status = 0 or 1
- Women of childbearing potential must have a negative serum pregnancy test within 30 days of starting study drug. A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months)
- Male or female of child-bearing potential must agree to use adequate contraceptive methods
- Serum bilirubin \< 2 mg/ml
- Serum creatinine \</= 1.5 mg/ml
- Serum ALT \< 2 x upper normal limit
- anti-neutrophil cytoplasmic antibody (cANCA) negative
- Not received specific therapy for MDS for 4 weeks. However, supportive therapy is permitted.
Exclusion
- Marrow blasts on aspirate \>/= 20%
- Blood blasts \> 1%
- Inaspirable bone marrow
- Myelosclerosis occupying \>30% of marrow space
- Iron absence on marrow examination or transferrin saturation \<20% and serum ferritin \<50ng/ml
- B-12 deficiency
- Folate deficiency
- History of immune related hematological disorder \[i.e.,immune thrombopenia purpura(ITP),autoimmune hemolytic anemia ( AIHA)\]
- Other causes of cytopenia not related to MDS (i.e., GI blood loss)
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form or that will place the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret the data
- Prior allogeneic or syngeneic transplant
- Prior solid organ transplant
- Life expectancy severely limited by diseases other than MDS
- Pregnant or lactating females
- Prior vaccine therapy for MDS
- Chronic use (\>2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to \>10 mg/day of prednisone) within 30 days of the first day of study drug treatment. (Topical and inhaled corticosteroids are permitted)
- Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for \>/= 5 years
- Known allergy to incomplete Freund's adjuvant
- Experimental therapy, cyclosporine, antithymocyte globulin, or FK506 within 3 months of study entry
- Treatment with androgenic hormones, danazol, colony stimulating factors, erythropoietin, thalidomide, arsenic trioxide or other agents used to treat MDS within four weeks of the first day of study treatment
- refractory anemia with excess blasts in transformation (RAEB-t) (French-American British (FAB) criteria ) or refractory anemia with excess blasts type2 (RAEB-2) (World Health Organization (WHO) criteria)
- Chloroma
- Hypercalcemia
- Progressive viral or bacterial infection. Patients are not eligible unless all infections are resolved and the patient has remained afebrile for seven days without antibiotics
- Cardiac disease of symptomatic nature or cardiac ejection fraction \< 40%
- Symptomatic pulmonary disease or FEV1, FVC and Carbon Monoxide Diffusing Capacity (DLCO) \</= 50% predicted
- History of Wegener's Granulomatosis or vasculitis
- History of HIV positivity or AIDS
- Prior history of AML
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00893997
Start Date
July 1 2006
End Date
March 1 2009
Last Update
July 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.T. M.D. Anderson Cancer Center
Houston, Texas, United States, 77030